LA based Lundin Law PC has said that it is investigating claims against Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s” or the “Company”) (NYSE: RDY) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Dr. Reddy’s were false and misleading concerning the Company’s financial performance.
It has made a general appeal to join a class action suit. On November 6, 2015, Dr. Reddy’s Laboratories announced that it received a warning letter from the U.S. Food and Drug Administration over inadequate quality control procedures at three manufacturing plants in India.
LA based #Lundin Law plans class action lawsuit against #Dr.@drreddys ’ Laboratories pic.twitter.com/GttSxAE9zX
— Press Release Watch (@PrReleaseWatch) November 19, 2015
It has made a general appeal to join a class action suit. On November 6, 2015, Dr. Reddy’s Laboratories announced that it received a warning letter from the U.S. Food and Drug Administration over inadequate quality control procedures at three manufacturing plants in India.
